Novel ADME biomarkers and HRMS move new medicines to patients faster

In this interview with Ragu Ramanathan (Pfizer; NY, USA), Ragu describes his current research focuses in measuring and quantitating drugs and metabolites in animal and human samples. Ragu discusses the key challenges associated with studying drug/drug interactions (DDI), the benefits of current technologies available for studying DDI and what to expect from the upcoming Special Focus Issue from Bioanalysis on ‘Novel LC–MS assays impacting CYP and transporter DDI evaluation’.

Related resources:

• An author’s perspective: Ragu Ramanathan on an LC–MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting polypeptide biomarkers
• Development of an Excel-based laboratory information management system for improving workflow efficiencies in early ADME screening
• Improving LC–MS throughput and capacity for rapid ADME screening: a case study

If you liked this interview, you might also like:

Allena Ji on the challenges of targeted biomarker quantitation by LC–MS
Interview with Rob Wheller on the challenges of large molecule bioanalysis by LC–MS
Interview with John Kellie on the challenges of large molecule bioanalysis